Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar ...

LAS VEGAS (KLAS) — The American International Motorcycle Expo is taking place at the Las Vegas Convention Center and features the latest products, technology, motorcycles, off-road vehicles, gear, and ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that ...

Lilly shared numerous updates recently on key regulatory, clinical, business development and other events, including: U.S. Food and Drug Administration (FDA) approval of Zepbound for a new ...

Lilly last month forecast total sales to be between $58 billion and $61 billion in 2025, banking on the launch of Mounjaro in new markets, including China, India, Brazil and Mexico, for both ...

Eli Lilly reiterated its fiscal 2025 sales guidance of $58 billion to $61 billion, noting that it expects to launch Mounjaro in new international markets throughout the year. Eli Lilly expects to ...

"We believe this potential new medicine can deliver even more weight loss than tirzepatide and it could potentially provide additional health benefits," Daniel Skovronsky, Lilly's chief scientific ...

The company adds that the midpoint represents approximately 32% growth compared to 2024, driven by new Lilly medicines such as Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla; approvals ...

The midpoint represents approximately 32% growth compared to 2024, driven by new Lilly medicines such as Zepbound, Mounjaro, Jaypirca, Ebglyss, Omvoh and Kisunla; approvals of new indications for ...

1 Lilly defines new products as select products launched since 2022, which currently consist of Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh and Zepbound. 2 Lilly defines Growth Products as ...

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes ...